APP, amyloid beta precursor protein, 351

N. diseases: 485; N. variants: 114
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 AlteredExpression disease BEFREE Moreover, as activation of δ-opioid receptor by a non-peptidic δ-opioid receptor agonist also modulates the expression, maturation and processing of amyloid precursor protein and β-secretase activity, the potential role of these effects on ischemic stroke caused dementia or Alzheimer's disease are also discussed. 31535637 2020
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 Biomarker disease BEFREE The purpose of this study was to examine the association between cognitive function and several serum miRNAs levels related to amyloid precursor protein (APP) proteolysis in a Japanese general population who had never been diagnosed with dementia. 30802839 2020
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 Biomarker disease BEFREE Cystatin isolated from chicken egg white, called ovocystatin, has been widely used in the medical and pharmaceutical research due to its structural and biological similarities to human cystatin C. The aim of this study was to assess the effect of administering ovocystatin on the development of dementia-specific cognitive deficits in APP/PS1 transgenic mice. 30504006 2019
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 Biomarker disease BEFREE Therefore, we exposed an AD-relevant mouse model (APP/PS1 KI) to chronic intermittent hypoxia (IH) (an experimental model of sleep apnea) to begin to describe one of the potential mechanisms by which SDB could increase the risk of dementia. 30529693 2019
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 Biomarker disease BEFREE The evidence that a pathogenic APP mutation causes an early enhancement of BAD-Glu suggests that alterations of BACE1 processing of APP in glutamatergic synaptic vesicles could contribute to dementia. 31496118 2019
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 GeneticVariation disease BEFREE Amyloid PET pattern with dementia and amyloid angiopathy in Taiwan familial AD with D678H APP mutation. 30703749 2019
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 GeneticVariation disease BEFREE 2) Family members with codon 717 APP mutations and dementia have low serum vitamin B12 values. 30814347 2019
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 Biomarker disease BEFREE Neuropsychiatric symptoms have been reported as prodromal symptoms of AD-like dementia and soluble forms of beta amyloid peptide (), the main constituent of insoluble plaques typical of AD brains, have been implicated in such an effect. 29879605 2018
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 Biomarker disease BEFREE BACE1 activity and sAβPPβ concentration were measured in patients with AD dementia (n = 56) and mild cognitive impairment (MCI) due to AD (n = 76) with abnormal routine AD CSF markers, in patients with MCI with normal CSF markers (n = 39), and in controls without preclinical AD (n = 48). 29788013 2018
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 AlteredExpression disease BEFREE We explored how levels of endocytic proteins, APP, its metabolites, secretase enzymes, and tau varied with age in cortical brain samples from men of three age ranges (young [20-30], middle aged [45-55], and old [70-90]) with no symptoms of dementia. 28655199 2018
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 Biomarker disease CTD_human High performance plasma amyloid-β biomarkers for Alzheimer's disease. 29420472 2018
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 Biomarker disease BEFREE Scrutiny of the evidence generated so far reveals and a lack of understanding of the wider APP proteolytic system and how narrow research into the dementia syndrome has been to date. 30246866 2018
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 Biomarker disease BEFREE APP is involved in the pathology of Alzheimer's disease (AD), the most common neurodegenerative disorder causing dementia. 29383688 2018
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 Biomarker disease CTD_human Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. 30320580 2018
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 GeneticVariation disease BEFREE We review current knowledge on clinical diagnosis and presentation of dementia in DS in comparison with FAD due to APP mutations and APP duplication. 28870521 2018
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 Biomarker disease BEFREE Also problematic is the alternative hypothesis that, instead of amyloid plaques, it is oligomers of amyloid precursor protein that cause AD.Evidence is presented suggesting amyloid/oligomers as necessary but insufficient causes of the dementia and that, for dementia to develop, requires the addition of cofactors known to be associated with AD. 28509380 2018
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 Biomarker disease BEFREE Alzheimer's disease (AD) is the most common cause of dementia and is likely caused by defective amyloid precursor protein (APP) trafficking and processing in neurons leading to amyloid plaques containing the amyloid-β (Aβ) APP peptide byproducts. 28360834 2017
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 Biomarker disease BEFREE An elderly man with phenotypic DS and partial trisomy of chromosome 21 (PT21) lacked triplication of APP affording an opportunity to study the role of this gene in the pathogenesis of dementia. 27983553 2017
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 GeneticVariation disease BEFREE Participants from five families with early-onset autosomal-dominant mutations (Swedish and Arctic APP, PSEN1 M146V, H163Y, and I143T) included 35 carriers (28 without dementia and 7 with) and 44 non-carriers. 28079014 2017
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 Biomarker disease CTD_human Oral administration of methysticin improves cognitive deficits in a mouse model of Alzheimer's disease. 28448946 2017
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 GeneticVariation disease BEFREE Mutations in amyloid β precursor protein (APP) gene alter APP processing, either causing familial Alzheimer's disease (AD) or protecting against dementia. 28626014 2017
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 Biomarker disease CTD_human The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer's Disease. 27117003 2016
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 GeneticVariation disease BEFREE Trisomy 21 and the consequent extra copy of the amyloid precursor protein (APP) gene and increased beta-amyloid (Aβ) peptide production underlie the universal development of Alzheimer's disease (AD) pathology and high risk of AD dementia in people with Down syndrome (DS). 26651340 2016
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 GeneticVariation disease BEFREE Given the absence of PSEN1, PSEN2 and APP causative variants, we investigated whether these 260 patients might be burdened with protein-modifying variants in 20 genes that were previously shown to cause other types of dementia when mutated. 26242991 2016
CUI: C0011265
Disease: Presenile dementia
Presenile dementia
0.400 Biomarker disease CTD_human Identification of the key molecules involved in chronic copper exposure-aggravated memory impairment in transgenic mice of Alzheimer's disease using proteomic analysis. 25352456 2015